Incidensen af tilbagefald under den 6- måneders dobbeltblinde follow- up periode var 14% for CYMBALTA og 42% for placebo.
The incidence of relapse during the 6-months double-blind follow-up period was 14% for CYMBALTA and 42% for placebo.